Re: Re: ** New Research: Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer

[Guest guest]

I couldn't agree more. How do you quantify the risk too. For me I have 3 times the risk of a normal person - maybe more because the average RAI is 100 - 150 mCi's and I had 100, 150 and 250 mCi's. So probably 5 times the amount of a *normal* person.

Steph

Re: ** New Research: Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer

Ya know, it's sad that they actually had to do "research" to confirm the obvious.Lorie>> http://www.liebertonline.com/doi/pdfplus/10.1089/thy.2008.0392> > Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis> > M. Sawka, Lehana Thabane, Luciana Parlea, Irada Ibrahim-Zada, W. Tsang, D. Brierley, Sharon Straus, Shereen Ezzat, P. Goldstein > Thyroid. May 2009, 19(5): 451-457.> >> Results: Two multi-center studies (one from Europe and the other from North America) were included in this review. The RR of SPMs in thyroid cancer survivors treated with RAI was significantly increased at 1.19 (95% confidence interval [CI] 1.04, 1.36, p=0.010), relative to thyroid cancer survivors not treated with RAI (data from 16,502 individuals), using a minimum latency period of 2 to 3 years after thyroid cancer diagnosis. The RR of leukemia was also significantly increased in thyroid cancer survivors treated with RAI, with an RR of 2.5 (95% CI 1.13, 5.53, p=0.024). We did not observe a significantly increased risk of the following cancers related to prior RAI treatment: bladder, breast, central nervous system, colon and rectum, digestive tract, stomach, pancreas, kidney (and renal pelvis), lung, or melanoma of skin.> > Conclusions: The risk of SPMs in thyroid cancer survivors treated with RAI is slightly increased compared to thyroid cancer survivors not treated with RAI.>